Efficacy of doxycycline versus azithromycin for the treatment of rectal chlamydia: A systematic review and meta-analysis

研究成果: 雜誌貢獻回顧型文獻同行評審

1 引文 斯高帕斯(Scopus)

摘要

Background: Chlamydia trachomatis infection is the most common sexually transmitted infectious disease and carries a risk of complications. However, the optimal treatment for rectal chlamydial infection remains unclear. Objectives: To compare the efficacy of doxycycline and azithromycin for the treatment of rectal chlamydia by undertaking a systematic review and meta-analysis of published data. Methods: We searched PubMed, EMBASE, Cochrane Library, Web of Science and clinicaltrials.gov databases from inception to 7 July 2021 for randomized controlled trials (RCTs) and observational studies that compared the efficacy of doxycycline and single-dose azithromycin on rectal chlamydia cure rates. Data were synthesized using a random-effects model, and subgroup analysis was conducted. Results: All included studies were conducted in developed countries. Two RCTs and nine observational studies, with a total of 2457 patients, were analysed. Doxycycline had a higher microbiological cure rate than azithromycin (risk ratio = 1.21; 95% CI = 1.15-1.28; P < 0.05). Pooled results from two RCTs also revealed a higher microbiological cure rate for doxycycline than azithromycin (risk ratio = 1.27; 95% CI = 1.20-1.35; P < 0.05). The results remained consistent in subgroups of different study designs, countries and sexes. Conclusions: On the basis of our findings, we recommend doxycycline rather than azithromycin as a first-line treatment for rectal chlamydia in developed countries. More RCTs from developing countries are warranted.
原文英語
頁(從 - 到)3103-3110
頁數8
期刊Journal of Antimicrobial Chemotherapy
76
發行號12
DOIs
出版狀態已發佈 - 12月 1 2021

ASJC Scopus subject areas

  • 藥理
  • 微生物學(醫學)
  • 傳染性疾病
  • 藥學(醫學)

指紋

深入研究「Efficacy of doxycycline versus azithromycin for the treatment of rectal chlamydia: A systematic review and meta-analysis」主題。共同形成了獨特的指紋。

引用此